{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MYD88+Gene+Mutation",
    "query": {
      "condition": "MYD88 Gene Mutation"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:50:17.865Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05233033",
      "title": "Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Hodgkin Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "DLBCL",
        "MYD88 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "KT-413",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kymera Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2022-06-13",
      "completion_date": "2023-07-28",
      "has_results": false,
      "last_update_posted_date": "2024-12-10",
      "last_synced_at": "2026-05-22T04:50:17.865Z",
      "location_count": 6,
      "location_summary": "Washington D.C., District of Columbia • Louisville, Kentucky • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05233033"
    },
    {
      "nct_id": "NCT06846463",
      "title": "Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma",
        "DLBCL - Diffuse Large B Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Zanubrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2025-05-27",
      "completion_date": "2032-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-05-22T04:50:17.865Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06846463"
    },
    {
      "nct_id": "NCT02252146",
      "title": "Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "IMO-8400",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Idera Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2014-06",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2017-12-12",
      "last_synced_at": "2026-05-22T04:50:17.865Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • Decatur, Illinois + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Illinois"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02252146"
    },
    {
      "nct_id": "NCT04273139",
      "title": "Ibrutinib + Venetoclax in Untreated WM",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Waldenstrom Macroglobulinemia",
        "MYD88 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "IBRUTINIB",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2020-07-09",
      "completion_date": "2028-02-01",
      "has_results": true,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-05-22T04:50:17.865Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04273139"
    }
  ]
}